HRP20180282T1 - Imunoterapija na bazi indoleamin 2, 3-dioksigenaze - Google Patents
Imunoterapija na bazi indoleamin 2, 3-dioksigenaze Download PDFInfo
- Publication number
- HRP20180282T1 HRP20180282T1 HRP20180282TT HRP20180282T HRP20180282T1 HR P20180282 T1 HRP20180282 T1 HR P20180282T1 HR P20180282T T HRP20180282T T HR P20180282TT HR P20180282 T HRP20180282 T HR P20180282T HR P20180282 T1 HRP20180282 T1 HR P20180282T1
- Authority
- HR
- Croatia
- Prior art keywords
- adjuvant
- seq
- use according
- vaccine preparation
- peptide
- Prior art date
Links
- 108020004201 indoleamine 2,3-dioxygenase Proteins 0.000 title claims 3
- 102000006639 indoleamine 2,3-dioxygenase Human genes 0.000 title claims 3
- 238000009169 immunotherapy Methods 0.000 title 1
- 229960005486 vaccine Drugs 0.000 claims 10
- 239000002671 adjuvant Substances 0.000 claims 8
- 108090000765 processed proteins & peptides Proteins 0.000 claims 6
- 238000011282 treatment Methods 0.000 claims 5
- 108010033276 Peptide Fragments Proteins 0.000 claims 3
- 102000007079 Peptide Fragments Human genes 0.000 claims 3
- 150000001413 amino acids Chemical class 0.000 claims 3
- 238000000034 method Methods 0.000 claims 3
- 102000004457 Granulocyte-Macrophage Colony-Stimulating Factor Human genes 0.000 claims 2
- 108010017213 Granulocyte-Macrophage Colony-Stimulating Factor Proteins 0.000 claims 2
- 206010028980 Neoplasm Diseases 0.000 claims 2
- 238000011319 anticancer therapy Methods 0.000 claims 2
- 201000011510 cancer Diseases 0.000 claims 2
- 230000002265 prevention Effects 0.000 claims 2
- 108091032973 (ribonucleotides)n+m Proteins 0.000 claims 1
- 102000040650 (ribonucleotides)n+m Human genes 0.000 claims 1
- 108020000946 Bacterial DNA Proteins 0.000 claims 1
- 125000000539 amino acid group Chemical group 0.000 claims 1
- 238000002512 chemotherapy Methods 0.000 claims 1
- 210000004443 dendritic cell Anatomy 0.000 claims 1
- 239000003814 drug Substances 0.000 claims 1
- 238000001415 gene therapy Methods 0.000 claims 1
- 239000003022 immunostimulating agent Substances 0.000 claims 1
- 238000001959 radiotherapy Methods 0.000 claims 1
- 239000004094 surface-active agent Substances 0.000 claims 1
- 230000003612 virological effect Effects 0.000 claims 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/19—Cytokines; Lymphokines; Interferons
- A61K38/193—Colony stimulating factors [CSF]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/19—Cytokines; Lymphokines; Interferons
- A61K38/20—Interleukins [IL]
- A61K38/2013—IL-2
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0011—Cancer antigens
- A61K39/001154—Enzymes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/0004—Oxidoreductases (1.)
- C12N9/0069—Oxidoreductases (1.) acting on single donors with incorporation of molecular oxygen, i.e. oxygenases (1.13)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Y—ENZYMES
- C12Y113/00—Oxidoreductases acting on single donors with incorporation of molecular oxygen (oxygenases) (1.13)
- C12Y113/11—Oxidoreductases acting on single donors with incorporation of molecular oxygen (oxygenases) (1.13) with incorporation of two atoms of oxygen (1.13.11)
- C12Y113/11052—Indoleamine 2,3-dioxygenase (1.13.11.52), i.e. indoleamine 2,3-dioxygenase 1
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/515—Animal cells
- A61K2039/5158—Antigen-pulsed cells, e.g. T-cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
- A61K2039/55566—Emulsions, e.g. Freund's adjuvant, MF59
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
- A61K2039/572—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2 cytotoxic response
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Organic Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Immunology (AREA)
- Zoology (AREA)
- Epidemiology (AREA)
- Wood Science & Technology (AREA)
- Genetics & Genomics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Microbiology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Gastroenterology & Hepatology (AREA)
- Biochemistry (AREA)
- General Engineering & Computer Science (AREA)
- Oncology (AREA)
- Mycology (AREA)
- Biotechnology (AREA)
- Biomedical Technology (AREA)
- Molecular Biology (AREA)
- Transplantation (AREA)
- Communicable Diseases (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Enzymes And Modification Thereof (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
Claims (12)
1. Pripravak cjepiva, koji sadrži:
a) imunogenski aktivni peptidni fragment indoleamin 2,3-dioksigenaze (IDO) sa SEQ ID NO:1, koji se sastoji od najviše 25 uzastopnih aminokiselina sa SEQ ID NO:1 koje sadrže sekvencu SEQ ID NO:6; i
b) adjuvans za primjenu u svrhu lijeka.
2. Pripravak cjepiva za primjenu prema zahtjevu 1, naznačen time, što spomenuti imunogenski aktivni peptidni fragment
a) ima najviše 11 aminokiselina u dužini; ili
b) ima od 18 do 25 aminokiselina u dužini.
3. Pripravak cjepiva za primjenu prema zahtjevu 1 ili 2, naznačen time, što spomenuti imunogenski aktivni peptidni fragment sadrži SEQ ID NO:6.
4. Pripravak cjepiva za primjenu prema bilo kojem zahtjevu od 1 do 3, naznačen time, stoje adjuvans odabran iz grupe koja se sastoji od GM-CSF-a, adjuvansa na bazi bakterijske DNK, adjuvansa na bazi ulja/surfaktanta, adjuvansa na bazi virusne dsRNK i imidazokinilina.
5. Pripravak cjepiva za primjenu prema zahtjevu 4, naznačen time, što je adjuvans Montanide ISA adjuvans ili GM-CSF.
6. Pripravak cjepiva za primjenu prema zahtjevu 5, naznačen time, što je adjuvans Montanide ISA 51 ili Montanide ISA 720.
7. Izolirani peptid od najviše 25 uzastopnih aminokiselinskih ostataka sa SEQ ID NO:1, koji sadrži sekvencu SEQ ID NO:6.
8. Izolirani peptid prema zahtjevu 7 koji sadrži sekvencu SEQ ID NO:6.
9. Pripravak cjepiva za primjenu prema bilo kojem zahtjevu od 1 do 6, naznačen time, što spomenuta primjena predstavlja postupak za liječenje ili sprječavanje raka.
10. Peptid prema zahtjevu 7 ili 8 za primjenu u postupku za liječenje ili sprječavanje raka.
11. Cjepivo ili peptid za primjenu prema zahtjevu 9 ili 10, naznačen time, što se postupak sastoji od primjene spomenutog cjepiva ili peptida u kombinaciji s dodatnom terapijom protiv raka.
12. Cjepivo ili peptid za primjenu prema zahtjevu 11, naznačeno time, stoje dodatna terapija protiv raka odabrana iz grupe koja se sastoji od kemoterapije, radioterapije, liječenja imunostimulirajućim sredstvima, genske terapije, liječenja antitijelima i liječenja pomoću dendritičkih stanica.
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| DKPA200800565 | 2008-04-17 | ||
| PCT/DK2009/000095 WO2009143843A1 (en) | 2008-04-17 | 2009-04-17 | Indoleamine 2, 3-dioxygenase based immunotherapy |
| EP09753556.1A EP2280721B1 (en) | 2008-04-17 | 2009-04-17 | Indoleamine 2, 3-dioxygenase based immunotherapy |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| HRP20180282T1 true HRP20180282T1 (hr) | 2018-03-23 |
Family
ID=40873320
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| HRP20180282TT HRP20180282T1 (hr) | 2008-04-17 | 2018-02-15 | Imunoterapija na bazi indoleamin 2, 3-dioksigenaze |
| HRP20210766TT HRP20210766T1 (hr) | 2008-04-17 | 2021-05-13 | Imunoterapija na bazi indoleamin 2, 3-dioksigenaze |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| HRP20210766TT HRP20210766T1 (hr) | 2008-04-17 | 2021-05-13 | Imunoterapija na bazi indoleamin 2, 3-dioksigenaze |
Country Status (20)
| Country | Link |
|---|---|
| US (6) | US9433666B2 (hr) |
| EP (3) | EP2280721B1 (hr) |
| JP (2) | JP2011520783A (hr) |
| CN (2) | CN104056261B (hr) |
| AU (1) | AU2009253539B2 (hr) |
| CA (1) | CA2721150C (hr) |
| CY (2) | CY1120352T1 (hr) |
| DK (2) | DK3320912T3 (hr) |
| ES (2) | ES2870596T3 (hr) |
| HR (2) | HRP20180282T1 (hr) |
| HU (2) | HUE055338T2 (hr) |
| IL (1) | IL208781A (hr) |
| LT (2) | LT3320912T (hr) |
| NO (1) | NO2280721T3 (hr) |
| NZ (1) | NZ588757A (hr) |
| PL (2) | PL3320912T3 (hr) |
| PT (2) | PT3320912T (hr) |
| SI (2) | SI2280721T1 (hr) |
| WO (1) | WO2009143843A1 (hr) |
| ZA (1) | ZA201008056B (hr) |
Families Citing this family (24)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| PL3320912T3 (pl) | 2008-04-17 | 2021-10-25 | Io Biotech Aps | Immunoterapia na bazie 2,3-dioksygenazy indoloaminy |
| EP2425830A1 (en) * | 2010-09-03 | 2012-03-07 | Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. | Synergistic drug combination for the treatment of cancer |
| GB201315946D0 (en) * | 2013-09-06 | 2013-10-23 | Immune Targeting Systems Its Ltd | Oncology vaccine |
| WO2015181266A1 (en) * | 2014-05-29 | 2015-12-03 | Spring Bioscience Corporation | Anti- indoleamine 2,3-dioxygenase 1 antibodies and diagnostic uses thereof |
| DK3193917T3 (da) | 2014-09-17 | 2021-10-04 | Io Biotech Aps | Vaccinesammensætninger, der omfatter tryptophan-2,3-dioxygenase eller fragmenter deraf |
| CN106148276A (zh) * | 2015-04-16 | 2016-11-23 | 中国科学院上海生命科学研究院 | 间充质干细胞在制备治疗神经退行性疾病的药物中的应用 |
| KR102571745B1 (ko) | 2015-06-29 | 2023-08-25 | 오제 이뮈노테라프틱스 | 짧은 펩타이드 항-암 백신을 이용하여 초기 t 기억 반응을 유도하는 방법 |
| IL257940B (en) | 2015-09-16 | 2022-08-01 | Herlev Hospital | Vaccines that include the CC motif. Chemokine 22 or fragments thereof |
| HUE064857T2 (hu) | 2016-03-04 | 2024-04-28 | Io Biotech Aps | Kombinációs terápia a rák ellen |
| EP3468585A2 (en) | 2016-06-10 | 2019-04-17 | IO Biotech APS | Calr and jak2 vaccine compositions |
| US11603394B2 (en) | 2016-10-04 | 2023-03-14 | University Of Florida Research Foundation, Incorporated | Targeted effector proteins and uses thereof |
| DK3526347T3 (da) * | 2016-10-14 | 2021-02-15 | Univ Zuerich | Indolamin-2,3-dioxygenase-analyse til diagnose og prognose af prostatacancer |
| KR20190124214A (ko) * | 2017-01-20 | 2019-11-04 | 아타라 바이오테라퓨틱스 인크. | 자가 t 세포를 사용하여 다발성 경화증을 치료하는 방법 |
| WO2018138257A1 (en) * | 2017-01-27 | 2018-08-02 | Immatics Biotechnologies Gmbh | Novel peptides and combination of peptides for use in immunotherapy against ovarian cancer and other cancers |
| SG11201906198PA (en) | 2017-01-27 | 2019-08-27 | Immatics Biotechnologies Gmbh | Novel peptides and combination of peptides for use in immunotherapy against ovarian cancer and other cancers |
| AR110857A1 (es) | 2017-01-27 | 2019-05-08 | Immatics Biotechnologies Gmbh | Péptidos y combinaciones de péptidos para el uso en la inmunoterapia contra el cáncer de ovario y otros tipos de cáncer |
| US11407797B2 (en) | 2017-10-11 | 2022-08-09 | University Of Florida Research Foundation, Incorporated | Modified gal-1 proteins and uses thereof |
| WO2019101347A1 (en) | 2017-11-27 | 2019-05-31 | Ose Immunotherapeutics | Improved treatment of cancer |
| CN109758467B (zh) * | 2019-03-08 | 2020-12-25 | 中国农业科学院兰州兽医研究所 | 一种吉西他滨在制备预防口蹄疫病毒感染的药物中的应用 |
| AU2020371562A1 (en) * | 2019-10-23 | 2022-06-09 | The Council Of The Queensland Institute Of Medical Research | Adoptive immunotherapy |
| CN112881269A (zh) * | 2021-02-23 | 2021-06-01 | 浙江正熙生物技术股份有限公司 | 一种流式荧光检测试剂的质量检测方法 |
| GB202103673D0 (en) | 2021-03-17 | 2021-04-28 | Io Biotech Aps | Combination therapy for cancer |
| WO2023161350A1 (en) | 2022-02-24 | 2023-08-31 | Io Biotech Aps | Nucleotide delivery of cancer therapy |
| CN114657158B (zh) * | 2022-05-25 | 2022-10-21 | 深圳吉诺因生物科技有限公司 | Ido1相关疫苗及其应用 |
Family Cites Families (37)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US58767A (en) | 1866-10-16 | John brougjbton | ||
| US5554372A (en) | 1986-09-22 | 1996-09-10 | Emory University | Methods and vaccines comprising surface-active copolymers |
| WO1997000966A1 (en) * | 1995-06-20 | 1997-01-09 | Merck & Co., Inc. | Conversion of indene to (1s)-amino-(2r)-indanol free of any stereoisomer, by combination of dioxygenase bioconversion and chemical steps |
| US6096313A (en) | 1996-02-09 | 2000-08-01 | Ludwig Institute For Cancer Research | Compositions containing immunogenic molecules and granulocyte-macrophage colony stimulating factor, as an adjuvant |
| WO1997047271A2 (en) | 1996-06-12 | 1997-12-18 | Yajun Guo | Cellular vaccines and immunotherapeutics and methods for their preparation |
| CN1223688A (zh) * | 1996-06-27 | 1999-07-21 | 纳幕尔杜邦公司 | 对羟基苯丙酮酸双加氧酶的植物基因 |
| DE19730066A1 (de) * | 1997-07-14 | 1999-01-21 | Basf Ag | DNA-Sequenz codierend für eine Hydroxyphenylpyruvatdioxygenase und deren Überproduktion in Pflanzen |
| US6395876B1 (en) | 1997-12-05 | 2002-05-28 | Medical College Of Georgia Research Institute, Inc. | High-affinity tryptophan transporter |
| WO2000066764A1 (en) | 1999-05-03 | 2000-11-09 | Ludwig Institute For Cancer Research | Methods for increasing t cell proliferation |
| MXPA03006617A (es) | 2001-01-24 | 2004-12-02 | Protein Design Labs Inc | Metodos de diagnostico de cancer de pecho, composiciones y metodos de rastreo de moduladores de cancer de pecho. |
| US20030087250A1 (en) | 2001-03-14 | 2003-05-08 | Millennium Pharmaceuticals, Inc. | Nucleic acid molecules and proteins for the identification, assessment, prevention, and therapy of ovarian cancer |
| WO2003012061A2 (en) | 2001-08-01 | 2003-02-13 | Coley Pharmaceutical Gmbh | Methods and compositions relating to plasmacytoid dendritic cells |
| WO2003020884A2 (en) | 2001-08-14 | 2003-03-13 | The Government Of The United States Of America As Represented By The Secretary Of Health And Human Services | Method for rapid generation of mature dendritic cells |
| US20060292618A1 (en) | 2002-04-12 | 2006-12-28 | Mellor Andrew L | Antigen-presenting cell populations and their use as reagents for enhancing or reducing immune tolerance |
| WO2003087347A1 (en) | 2002-04-12 | 2003-10-23 | Medical College Of Georgia Research Institute, Inc. | Antigen-presenting cell populations and their use as reagents for enhancing or reducing immune tolerance |
| DE10229872A1 (de) * | 2002-07-03 | 2004-01-29 | Curevac Gmbh | Immunstimulation durch chemisch modifizierte RNA |
| US20040253606A1 (en) | 2002-11-26 | 2004-12-16 | Protein Design Labs, Inc. | Methods of detecting soft tissue sarcoma, compositions and methods of screening for soft tissue sarcoma modulators |
| WO2004053075A2 (en) | 2002-12-05 | 2004-06-24 | Diadexus, Inc. | Compositions, splice variants and methods relating to breast specific genes and proteins |
| MXPA05006306A (es) | 2002-12-13 | 2005-09-21 | Mitra Medical Technology Ab | Agentes de direccionamiento antilinfoma con funciones efectoras y de afinidad enlazados a traves de un reactivo trifuncional. |
| DE10261223A1 (de) | 2002-12-20 | 2004-07-08 | MedInnova Gesellschaft für medizinische Innovationen aus akademischer Forschung mbH | Steigerung der Immunantwort durch Substanzen, welche die Funktion von Natürlichen Killerzellen beeinflussen |
| CA2520172C (en) | 2003-03-27 | 2012-10-02 | Lankenau Institute For Medical Research | Novel methods for the treatment of cancer with an indoleamine 2, 3-dioxygenase inhibitor |
| US20050186289A1 (en) | 2003-04-01 | 2005-08-25 | Medical College Of Georgia Research Institute, Inc. | Regulation of T cell-mediated immunity by D isomers of inhibitors of indoleamine-2,3-dioxygenase |
| US7598287B2 (en) | 2003-04-01 | 2009-10-06 | Medical College Of Georgia Research Institute, Inc. | Use of inhibitors of indoleamine-2,3-dioxygenase in combination with other therapeutic modalities |
| WO2005017163A2 (en) | 2003-08-15 | 2005-02-24 | Imperial College Innovations Limited | Phenotypic knockout of cell-surface proteins |
| WO2005036127A2 (en) | 2003-10-02 | 2005-04-21 | The Board Of Trustees Of The Leland Stanford Junior University | Methods and compositions for identifying target cell cytolytic lymphocytes in a sample |
| EP1773846A4 (en) * | 2004-07-13 | 2008-10-08 | Univ British Columbia | INHIBITORS OF INDOLEAMINE 2,3-DIOXYGENASE (IDO) |
| US20060110371A1 (en) | 2004-11-23 | 2006-05-25 | Institut Pasteur | Control of indoleamine 2,3 deoxygenase expression and activity |
| CA2593714C (en) | 2005-02-04 | 2013-09-10 | Survac Aps | Survivin peptide vaccine |
| PL1879573T3 (pl) | 2005-05-10 | 2013-05-31 | Incyte Holdings Corp | Modulatory 2,3-dioksygenazy indoloaminy i sposoby ich zastosowania |
| US7468186B2 (en) | 2005-07-22 | 2008-12-23 | City Of Hope | Polyomavirus cellular epitopes and uses therefor |
| GB0519303D0 (en) | 2005-09-21 | 2005-11-02 | Oxford Biomedica Ltd | Chemo-immunotherapy method |
| US20090130067A1 (en) * | 2005-09-23 | 2009-05-21 | Dirk Buscher | Cell Population Having Immunoregulatory Activity, Method for Isolation and Uses |
| US20070203140A1 (en) | 2006-02-09 | 2007-08-30 | Combs Andrew P | N-hydroxyguanidines as modulators of indoleamine 2,3-dioxygenase |
| WO2007115068A2 (en) | 2006-03-30 | 2007-10-11 | Indiana University Research And Technology Corporation | Genetic variants in the indoleamine 2,3-dioxygenase gene |
| EP2023715B1 (en) * | 2006-05-18 | 2014-01-08 | Lankenau Institute for Medical Research | Indoleamine-2, 3-dioxygenase-2 |
| US8507434B2 (en) * | 2007-01-03 | 2013-08-13 | The Johns Hopkins University | Peptide modulators of angiogenesis and use thereof |
| PL3320912T3 (pl) * | 2008-04-17 | 2021-10-25 | Io Biotech Aps | Immunoterapia na bazie 2,3-dioksygenazy indoloaminy |
-
2009
- 2009-04-17 PL PL17194619T patent/PL3320912T3/pl unknown
- 2009-04-17 NZ NZ588757A patent/NZ588757A/en unknown
- 2009-04-17 CA CA2721150A patent/CA2721150C/en active Active
- 2009-04-17 LT LTEP17194619.7T patent/LT3320912T/lt unknown
- 2009-04-17 PT PT171946197T patent/PT3320912T/pt unknown
- 2009-04-17 ES ES17194619T patent/ES2870596T3/es active Active
- 2009-04-17 NO NO09753556A patent/NO2280721T3/no unknown
- 2009-04-17 PL PL09753556T patent/PL2280721T3/pl unknown
- 2009-04-17 ES ES09753556.1T patent/ES2657963T3/es active Active
- 2009-04-17 CN CN201410247727.XA patent/CN104056261B/zh active Active
- 2009-04-17 SI SI200931791T patent/SI2280721T1/en unknown
- 2009-04-17 HU HUE17194619A patent/HUE055338T2/hu unknown
- 2009-04-17 LT LTEP09753556.1T patent/LT2280721T/lt unknown
- 2009-04-17 EP EP09753556.1A patent/EP2280721B1/en active Active
- 2009-04-17 DK DK17194619.7T patent/DK3320912T3/da active
- 2009-04-17 JP JP2011504314A patent/JP2011520783A/ja active Pending
- 2009-04-17 HU HUE09753556A patent/HUE037973T2/hu unknown
- 2009-04-17 PT PT97535561T patent/PT2280721T/pt unknown
- 2009-04-17 SI SI200932129T patent/SI3320912T1/sl unknown
- 2009-04-17 CN CN200980122844.0A patent/CN102088994B/zh active Active
- 2009-04-17 EP EP21157371.2A patent/EP3915570A1/en active Pending
- 2009-04-17 EP EP17194619.7A patent/EP3320912B1/en active Active
- 2009-04-17 DK DK09753556.1T patent/DK2280721T3/da active
- 2009-04-17 AU AU2009253539A patent/AU2009253539B2/en active Active
- 2009-04-17 US US12/988,124 patent/US9433666B2/en active Active
- 2009-04-17 WO PCT/DK2009/000095 patent/WO2009143843A1/en active Application Filing
-
2010
- 2010-10-17 IL IL208781A patent/IL208781A/en active IP Right Grant
- 2010-11-10 ZA ZA2010/08056A patent/ZA201008056B/en unknown
-
2015
- 2015-03-17 JP JP2015052888A patent/JP6016966B2/ja active Active
-
2016
- 2016-08-08 US US15/231,075 patent/US10258678B2/en active Active
-
2018
- 2018-02-12 CY CY20181100171T patent/CY1120352T1/el unknown
- 2018-02-15 HR HRP20180282TT patent/HRP20180282T1/hr unknown
-
2019
- 2019-01-29 US US16/261,114 patent/US11324813B2/en active Active
-
2021
- 2021-05-13 HR HRP20210766TT patent/HRP20210766T1/hr unknown
- 2021-06-28 CY CY20211100572T patent/CY1124279T1/el unknown
-
2022
- 2022-03-17 US US17/697,732 patent/US20220202922A1/en not_active Abandoned
- 2022-04-15 US US17/721,577 patent/US11648302B2/en active Active
-
2023
- 2023-04-10 US US18/298,263 patent/US20230233657A1/en active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| HRP20180282T1 (hr) | Imunoterapija na bazi indoleamin 2, 3-dioksigenaze | |
| US20210401966A1 (en) | Nucleic acid molecules and uses thereof | |
| US11739125B2 (en) | Respiratory syncytial virus (RSV) vaccine | |
| HRP20220924T1 (hr) | Imunoterapija zasnovana na pd-l1 | |
| JP2014534202A5 (hr) | ||
| AR107020A2 (es) | Vacuna de pcsk9 (proteína convertasa subtilisina-kexina tipo 9) | |
| AR086078A1 (es) | Proteinas de fusion y vacunas de combinacion | |
| NZ570553A (en) | Immunogenic peptide sequences from influenza A and B and uses thereof for vaccines | |
| MX2012008999A (es) | Composicion farmaceutica para el tratamiento y/o prevencion del cancer. | |
| MX2012008998A (es) | Composicion farmaceutica para el tratamiento y/o prevencion del cancer. | |
| MX2012009000A (es) | Composicion farmaceutica para el tratamiento y/o prevencion del cancer. | |
| MX340016B (es) | Composicion farmaceutica para el tratamiento y/o prevencion del cancer. | |
| BRPI0815578B8 (pt) | Peptídeo de cdca1, seu uso e composição imunogênica compreendendo o mesmo para induzir imunidade, tratar e/ou prevenir o câncer, bem como método in vitro para induzir uma célula apresentadora de antígeno e uma célula t citotóxica (killer) | |
| FI3423087T3 (fi) | Syövän vastainen yhdistelmähoito | |
| AR065076A1 (es) | Vacuna contra el papilomavirus | |
| WO2016100328A8 (en) | Novel tilapia virus and uses thereof | |
| CL2012000447A1 (es) | Composición o vacuna que comprende un vector viral de un paramixovirus aviar 8 (apmv-8) recombinante; método para producir dicho vector; y uso para preparar medicamento útil para inducir una respuesta inmunológica. | |
| AR080111A1 (es) | Metodos y composiciones de inmunizacion | |
| AR083839A1 (es) | Virus del sindrome reproductivo y respiratorio porcino (prrs) de los estados unidos y sus usos | |
| RU2011110376A (ru) | Эпитопные пептиды hig2 и urlc10 и содержание их вакцины | |
| AR094725A1 (es) | Parvovirus 5a porcino, métodos de uso y vacuna | |
| HRP20240163T1 (hr) | Metode i pripravci za izazivanje zaštitnog imuniteta protiv infekcije filovirusom | |
| WO2014205579A4 (en) | Modified matrix proteins of vesicular stomatitis virus | |
| RU2010154101A (ru) | Пептиды эпитопов mybl2 и содержащие их вакцины | |
| EP4353256A3 (en) | Induction of cross-reactive cellular response against rhinovirus antigens |